FDA approves Eli Lilly’s Inluriyo for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer

An estimated 50% of patients with ER+, HER2– metastatic breast cancer will develop an ESR1 mutation during or after exposure to an aromatase inhibitor

Sanofi boosts Sanofi Ventures with additional $625 million September 24, 2025

Sanofi Ventures drives innovation through leading and participating in private financing rounds for pioneering healthcare companies

Aptar Pharma opens new R&D center in France

Expanded capabilities that continue to push the boundaries of innovation—advancing drug delivery solutions for patients, customers, and consumers around the world

Enhertu improved in invasive disease-free survival in early breast cancer in DB-05

Second positive Phase III trial of AstraZeneca and Daiichi Sankyo’s Enhertu in HER2-positive early breast cancer reinforces its potential to become a foundational treatment option in curative-intent setting

AstraZeneca to harmonise its listing structure across LSE, STO and NYSE

Harmonisation of listing structure requires a direct listing of AstraZeneca shares on the NYSE in place of existing US ADRs

European Commission approves Lilly’s Kisunla for treatment of early Alzheimer’s patients

Lupin acquires VISUfarma to strengthen specialty ophthalmology portfolio

Air Liquide bags contract in Spain to care for patients living with respiratory conditions at home

Air Liquide will provide care for people living with respiratory diseases such as chronic obstructive pulmonary disease (COPD) and sleep apnea

Moderna opens manufacturing and R&D facility in UK

The Moderna Innovation and Technology Centre in Harwell, Oxfordshire is now fully operational and Moderna is licensed to supply British-made COVID-19 vaccines to the UK population

Fujifilm Biotechnologies opens cell culture manufacturing site in North Carolina

Represents one of the largest cell culture biomanufacturing sites in North America, which will employ 1,400 people by 2031